# Sanofi

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/sanofi/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | US company, subsidiary of Sanofi |
| OpenAlex ID | https://openalex.org/F4320307781 |
| ROR ID | https://ror.org/027vj4x92 |
| Works | 50,207 |

## Funder papers

Showing 15 of 62.

- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes](https://scholariq.org/papers/glucose-control-and-vascular-complications-in-veterans-with-type-2-diabetes/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-continued-weekly-subcutaneous-semaglutide-vs-placebo-on-weight-loss/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis](https://scholariq.org/papers/2019-update-of-the-joint-european-league-against-rheumatism-and-european-renal/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study](https://scholariq.org/papers/effect-of-intensive-diabetes-treatment-on-albuminuria-in-type-1-diabetes-long/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.